Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right back to the highs of the day.
Strong.....
TGLO has been having some good days lately.
MWM was a big supporter a year ago.
Now?
Don't know.
Some sort of a wall now @ .0031 and .0032
Someone could get a very nice chunk of shares if they hit that Ask.
If someone does do that , it just might provide the needed oomph to .004
Great post , thanks for keeping us not so tech savvy wired.
DLOC is moving up .
https://www.digitallocations.com/
Check the Video.
Watch the video here.
Video is embedded on their company website too. https://www.digitallocations.com
"Disruptive Technology"
Simple Chart.
https://stockcharts.com/h-sc/ui?s=spzi
Number # 3 on the breakout board lists now.
Great post here this morning. By Jonnyrothrock
Starlink cannot stream high data/movies/meida/etc basically everything besides calling and texting……the internet browsing what everyone also wants.
This is what DLOC says they have accomplished. And perhaps Patented…we need more info. ….but this is a big deal because the DLOC tech breakthrough is through the cell phone itself…no satellite modification needed..…i.e.::: .the need to build bigger satellites or antennas on the current satellites like Elon had to do w some of his Starlinks satellites to accomplish just calls and texts cell phone to satellite.
DLOC has apparently cracked the code for high speed internet and data WITHOUT modifying ANY satellites!.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173833871
Just need a whale, or two to get us into the mid .003's now.
All harpooners to the deck please.
The melt - up is coming.
Nice volume today,
lets stay above that .0013 mark now.
Love the charts.
Fantastic looking for some good news soon.
Post of the day Award goes to you.
Correct.
Yes we are.
Ignore added.
Fantastic, thanks for keeping the rest of us informed.
Starting to look very smart for your buy.
Good job.
Draw attention?
I know it will make you a pile of cash though.
MRES looking good with the volume.
1 day big volume the next day nothing?
Break loose soon.
Imho
With tax loss selling over we will see
APSI start to bloom once again.
Huge volume for MRES at least 7x's , and a lot of day left.
Take out the seller, and then Up we Go.
MRES .0103
YES, huge volume for MRES
Take out the seller, and then Up we Go.
MRES on sale now.
I was able to pick up a few @ .0082
Added.
Here we going up now REVERSAL.
Now, nobody will get anything. Everyone gets , jack.
I never can understand that.
I would think there is 2 sides to this story.
Some where in the middle the truth lies.
There is much that we'll never know.
It would be nice to get an update someday.
Maybe recovery some $
Smartest post I have read in days.
Post of the day award too.
I have had them on ignore for years.
I Picked up 20k today at .0355 and .0354.
First Buy of anything in quit some time "added"
XCRT
I am off to see the wizard, the wonderful wizard of Oz.
We are on the yellow brick road here.
Wow up 100%. Congratulations to DIGITECH.
Ausome Contest
Maybe next time I will do better than Down 80%. Ya-think?
Again thank you sskillz1
NHMD fantastic. Thanks for your thoughts.
Agree
Excellent post Sterling. This post deserves a big sticky for sure. I'm excited as hell and can't wait for this to close this week! Thank You!!
Reading this board, and many others here on ihub
I have come to the conclusion
I know now why the World is so screwed up.
MRES
https://www.worldcoffeeportal.com/Latest/News/2021/May/Rand-Capital-Coffee-aspires-to-scale-Starbucks-acr
Rand Capital Coffee aspires to scale Starbucks across Africa
Rand Capital Coffee CEO Adrian Maizey has outlined his company’s vision to grow Starbucks’ presence beyond South Africa and across the African continent
M2Bio is set to collaborate with Rand Capital Coffee within the premises. Rand Capital, founded in 2010, oversees and manages over 70 premium coffee cafes across Southern Africa. The offices are at 1515 Palisades Drive, Pacific Palisades, CA.
Michael Sachar, CEO of M2Bio Sciences Food and Beverage, expressed excitement about the expansion, stating, "We are ecstatic about opening the M2Bio Sciences Food and Beverage offices in Los Angeles. Having a solid base in California allows us to gain a foothold on the West Coast as our rollout for North American distribution for 2024 gains momentum. We have seen phenomenal growth in the food division and are excited to share our premium health-centric products with new partners and consumers."
https://www.worldcoffeeportal.com/Latest/News/2021/May/Rand-Capital-Coffee-aspires-to-scale-Starbucks-acr
Rand Capital Coffee aspires to scale Starbucks across Africa
Rand Capital Coffee CEO Adrian Maizey has outlined his company’s vision to grow Starbucks’ presence beyond South Africa and across the African continent
MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office
Press Release | 11/14/2023
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 14, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:
M2Bio Sciences Food & Beverage strategically expands its presence by opening offices in Los Angeles, California. This move aims to broaden the distribution of Liviana™ and Medspresso™ products within the United States, aligning with the company's global commitment to providing healthy and trusted food products backed by evidence-based clinical science.
M2Bio is set to collaborate with Rand Capital Coffee within the premises. Rand Capital, founded in 2010, oversees and manages over 70 premium coffee cafes across Southern Africa. The offices are at 1515 Palisades Drive, Pacific Palisades, CA.
Michael Sachar, CEO of M2Bio Sciences Food and Beverage, expressed excitement about the expansion, stating, "We are ecstatic about opening the M2Bio Sciences Food and Beverage offices in Los Angeles. Having a solid base in California allows us to gain a foothold on the West Coast as our rollout for North American distribution for 2024 gains momentum. We have seen phenomenal growth in the food division and are excited to share our premium health-centric products with new partners and consumers."
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co
MRES News
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
Press Release | 11/03/2023
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:
The Annual Biomedical Research & Innovation Platform Symposium took place on the 16 th & 17 th of October 2023, with Prof Vinesh Maharaj as the first keynote speaker of this two-day event that delved into an electrifying exploration of innovation, tradition, and groundbreaking potential in the realm of biomedicine. Professor Maharaj holds the esteemed position of Deputy Dean of Research and Postgraduate Education at the University of Pretoria and Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research .
Professor Maharaj's presentation guides us on a historical journey of traditional plant-based medicine. It demonstrates how modern scientific insights can elucidate the mechanisms of action of various plants, fostering a collaborative partnership between traditional healers and conventional medical practitioners. Remarkably, more than half of all pharmaceutical drugs trace their origins to natural compounds, with 52% of medications being plant-derived. South Africa, boasting 24,000 plant species, ranks third globally in biodiversity. Notably, an impressive 20% of these species are unique to South Africa, found nowhere else in the world. To access the recording, please click here .
Maharaj highlights several well-known pharmaceuticals derived from plants, including Paclitaxel (PTX, used in cancer treatment), Quinine (an anti-malarial drug), Aspirin (with anti-inflammatory, analgesic, and antipyretic properties), and Morphine (an effective analgesic). Harnessing plants for drug development necessitates the identification of their active ingredients, a challenging task due to the multitude of compounds found in plants. This intricate process can take anywhere from 12 to 24 months to isolate, purify, and determine the structure of a single compound. In perspective, developing one FDA-approved drug typically demands screening through 10,000 compounds and may span several years.
The proposed solution to making this process more efficient involves creating a natural product library and employing artificial intelligence for efficient screening, a concept introduced at the 22:57-minute mark. The University of Pretoria, equipped with 11,000 plant samples, is actively working on establishing a comprehensive database. Furthermore, they have devised a high-throughput extraction method for screening, enabling the retrieval of samples from a robotic storage database for the subsequent generation of biological assays, facilitating the screening and analysis of potentially beneficial compounds.
At the 31:18-minute timestamp, Professor Vinesh discusses their compelling findings that demonstrate the efficacy of African ginger ( Siphonochilus aethiopicus ) against SARS-CoV-2, encompassing the Wuhan, delta, and beta variants, as well as influenza viruses. These effects were observed at concentrations comparable to standard control drugs used in respective assays[1]. Respiratory viral diseases, including COVID-19 and influenza, threaten global health, societal stability, and the economy. Despite the availability of numerous vaccines and treatments for these conditions, seasonal influenza alone still accounts for an estimated 3 to 5 million cases of severe illness and approximately 290,000 to 650,000 respiratory-related fatalities each year on a global scale. Consequently, there is a pressing need for the discovery and development of a more cost-effective and productive treatment regimen, ideally one with dual activity against these respiratory viral diseases, given the likelihood of co-infections[2]. The University of Pretoria has recently filed a patent for using African ginger in the fight against COVID-19, marking one of the leading research initiatives within M2Bio Sciences, an entity driven by artificial intelligence and machine learning, as highlighted at the 39:10-minute mark.
"Professor Vinesh Maharaj's keynote presentation during the Annual Biomedical Research & Innovation Platform Symposium illuminated the potent antiviral properties of African ginger in combating both influenza and SARS-CoV-2. This revelation was underscored by the exceptional synergy of integrating natural remedies and artificial intelligence. Collectively, our findings unveil a promising trajectory for healthcare innovation, where the harmonious convergence of traditional approaches and cutting-edge technology is poised to have a profound impact on life-saving interventions," articulated Jeff Robinson, Chief Executive Officer of M2Bio Sciences.
Professor Vinesh Maharaj, a distinguished figure in Research and Postgraduate Education within the Faculty of Natural and Agricultural Sciences, is a natural product chemist with expertise in discovering novel drug candidates derived from biodiversity samples. His primary objective centers around establishing a unique repository of natural products, encompassing a remarkable 10,000 plant specimens. This repository, a pioneering African endeavor, is the foundation for an innovative library. These plant samples are adeptly transformed into high throughput screening formats, primed for rigorous biological assessments to combat diseases like HIV, malaria, cancer, and COVID-19.
Through his efforts, he secured funding from the Department of Science and Innovation (DSI) to institute this pivotal platform, thus ensuring the availability of these invaluable resources to the national innovation system. This infrastructure is well-appointed with cutting-edge hyphenated analytical equipment, instrumental in the comprehensive chemical characterization of the library.
Furthermore, Professor Maharaj is the Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research, overseeing the natural product research endeavors conducted at the university on behalf of M2Bio Sciences.
To access the recording, please click here .
[1] https://repository.up.ac.za/handle/2263/78055 , Provisional Patent - Ref No.PA177413/P 1 and SA Patent Application No. 2022/11187 (Inventors - V. Maharaj, L. Invernizzi and P. Moyo).[2] https://journals.asm.org/doi/10.1128/jvi.01873-21
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co
MRES News
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
Press Release | 11/03/2023
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:
The Annual Biomedical Research & Innovation Platform Symposium took place on the 16 th & 17 th of October 2023, with Prof Vinesh Maharaj as the first keynote speaker of this two-day event that delved into an electrifying exploration of innovation, tradition, and groundbreaking potential in the realm of biomedicine. Professor Maharaj holds the esteemed position of Deputy Dean of Research and Postgraduate Education at the University of Pretoria and Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research .
Professor Maharaj's presentation guides us on a historical journey of traditional plant-based medicine. It demonstrates how modern scientific insights can elucidate the mechanisms of action of various plants, fostering a collaborative partnership between traditional healers and conventional medical practitioners. Remarkably, more than half of all pharmaceutical drugs trace their origins to natural compounds, with 52% of medications being plant-derived. South Africa, boasting 24,000 plant species, ranks third globally in biodiversity. Notably, an impressive 20% of these species are unique to South Africa, found nowhere else in the world. To access the recording, please click here .
Maharaj highlights several well-known pharmaceuticals derived from plants, including Paclitaxel (PTX, used in cancer treatment), Quinine (an anti-malarial drug), Aspirin (with anti-inflammatory, analgesic, and antipyretic properties), and Morphine (an effective analgesic). Harnessing plants for drug development necessitates the identification of their active ingredients, a challenging task due to the multitude of compounds found in plants. This intricate process can take anywhere from 12 to 24 months to isolate, purify, and determine the structure of a single compound. In perspective, developing one FDA-approved drug typically demands screening through 10,000 compounds and may span several years.
The proposed solution to making this process more efficient involves creating a natural product library and employing artificial intelligence for efficient screening, a concept introduced at the 22:57-minute mark. The University of Pretoria, equipped with 11,000 plant samples, is actively working on establishing a comprehensive database. Furthermore, they have devised a high-throughput extraction method for screening, enabling the retrieval of samples from a robotic storage database for the subsequent generation of biological assays, facilitating the screening and analysis of potentially beneficial compounds.
At the 31:18-minute timestamp, Professor Vinesh discusses their compelling findings that demonstrate the efficacy of African ginger ( Siphonochilus aethiopicus ) against SARS-CoV-2, encompassing the Wuhan, delta, and beta variants, as well as influenza viruses. These effects were observed at concentrations comparable to standard control drugs used in respective assays[1]. Respiratory viral diseases, including COVID-19 and influenza, threaten global health, societal stability, and the economy. Despite the availability of numerous vaccines and treatments for these conditions, seasonal influenza alone still accounts for an estimated 3 to 5 million cases of severe illness and approximately 290,000 to 650,000 respiratory-related fatalities each year on a global scale. Consequently, there is a pressing need for the discovery and development of a more cost-effective and productive treatment regimen, ideally one with dual activity against these respiratory viral diseases, given the likelihood of co-infections[2]. The University of Pretoria has recently filed a patent for using African ginger in the fight against COVID-19, marking one of the leading research initiatives within M2Bio Sciences, an entity driven by artificial intelligence and machine learning, as highlighted at the 39:10-minute mark.
"Professor Vinesh Maharaj's keynote presentation during the Annual Biomedical Research & Innovation Platform Symposium illuminated the potent antiviral properties of African ginger in combating both influenza and SARS-CoV-2. This revelation was underscored by the exceptional synergy of integrating natural remedies and artificial intelligence. Collectively, our findings unveil a promising trajectory for healthcare innovation, where the harmonious convergence of traditional approaches and cutting-edge technology is poised to have a profound impact on life-saving interventions," articulated Jeff Robinson, Chief Executive Officer of M2Bio Sciences.
Professor Vinesh Maharaj, a distinguished figure in Research and Postgraduate Education within the Faculty of Natural and Agricultural Sciences, is a natural product chemist with expertise in discovering novel drug candidates derived from biodiversity samples. His primary objective centers around establishing a unique repository of natural products, encompassing a remarkable 10,000 plant specimens. This repository, a pioneering African endeavor, is the foundation for an innovative library. These plant samples are adeptly transformed into high throughput screening formats, primed for rigorous biological assessments to combat diseases like HIV, malaria, cancer, and COVID-19.
Through his efforts, he secured funding from the Department of Science and Innovation (DSI) to institute this pivotal platform, thus ensuring the availability of these invaluable resources to the national innovation system. This infrastructure is well-appointed with cutting-edge hyphenated analytical equipment, instrumental in the comprehensive chemical characterization of the library.
Furthermore, Professor Maharaj is the Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research, overseeing the natural product research endeavors conducted at the university on behalf of M2Bio Sciences.
To access the recording, please click here .
[1] https://repository.up.ac.za/handle/2263/78055 , Provisional Patent - Ref No.PA177413/P 1 and SA Patent Application No. 2022/11187 (Inventors - V. Maharaj, L. Invernizzi and P. Moyo).[2] https://journals.asm.org/doi/10.1128/jvi.01873-21
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co